Home » GE's 'Cellular Pharmacogenomics' Deal With TGen Could Promote HCS Use in Personalized Medicine

GE's 'Cellular Pharmacogenomics' Deal With TGen Could Promote HCS Use in Personalized Medicine

Jul 14, 2006
Premium

GE Healthcare's recently announced "cellular pharmacogenomics" partnership with the Phoenix, Ariz.-based Translational Genomics Research Institute may show HCS to be a useful tool for genomics-based drug development and eventually, personalized medicine.

The alliance, which is built around GE's IN Cell Analyzer high-content screening platform, is also part of the firm's broader strategy to partner with research institutions that can push its technologies into personalized medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

And Deal

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

For Long Life

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

Positive Review

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

This Week in Nucleic Acids Research

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.